|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer Statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011.
|
|
2
|
Herbst RS, Heymach JV and Lippman SM: Lung
Cancer. N Engl J Med. 359:1367–1380. 2008.
|
|
3
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Role of adjuvant chemotherapy in patients
with resected non-small cell lung cancer: reappraisal with a
meta-analysis of randomized controlled trials. J Clin Oncol.
22:3860–3867. 2004.
|
|
4
|
Wu W, Baxter JE, Wattam SL, et al:
Alternative splicing controls nuclear translocation of the cell
cycle-regulated NEK2 kinase. J Biol Chem. 282:26431–26440.
2007.
|
|
5
|
Sankaran S and Parvin JD: Centrosome
functions in normal and tumor cells. J Cell Biochem. 99:1240–1250.
2006.
|
|
6
|
Tsunoda N, Kokuryo T, Oda K, et al: Nek2
as a novel molecular target for the treatment of breast carcinoma.
Cancer Sci. 100:111–116. 2009.
|
|
7
|
Rees M, Stahl M, Klump B, Willers R,
Gabbert HE and Sarbia M: The prognostic significance of
proliferative activity, apoptosis and expression of DNA
topoisomerase II alpha in multimodally-treated esophageal squamous
cell carcinoma. Anticancer Res. 21:3637–3642. 2001.
|
|
8
|
Pugsley JM, Schmidt RA and Vesselle H: The
KI-67index and survival in non-small cell lung cancer: a review and
relevance to position emission tomography. Cancer J. 8:222–233.
2002.
|
|
9
|
Daidone MG and Silvestrini R: Prognostic
and predictive role of proliferation indices in adjuvant therapy of
breast cancer. J Natl Cancer Inst Monogr. 2001.27–35
|
|
10
|
Lara PC, Rey A, Santana C, Afonso JL, Diaz
JM, Gonzalez GJ, et al: The role of Ki67 proliferation assessment
in predicting local control in bladder cancer patients treated by
radical radiation therapy.
|
|
11
|
Shepherd NA, Richman PI and England J:
Ki67 derived proliferative activity in colorectal adenocarcinoma
with prognostic correlations. J Pathol. 155:213–219. 1988.
|
|
12
|
Toyokawa G, Masuda K, Daigo Y, Cho HS,
Yoshimatsu M, Takawa M, et al: Mini chromosome maintenance protein
7 is a potential therapeutic target in human cancer and a novel
prognostic marker of non-small cell lung cancer. Mol Cancer.
10:652011.
|
|
13
|
Scholzen T and Gerdes J: The Ki67 protein:
from the known and the unknown. J Cell Physiol. 182:311–322.
2000.
|
|
14
|
Lei M and Tye BK: Initiating DNA
synthesis: from recruiting to activating the MCM complex. J Cell
Sci. 114:1447–1454. 2001.
|
|
15
|
Zhong X, Li M, Nie B, et al:
Overexpression of RACK1 and CD147 associated with poor prognosis in
stage T1 pulmonarey adenocarcinoma. Ann Surg Oncol. 20:1044–1052.
2013.
|
|
16
|
Remmele W and Schicketanz KH:
Immunohistochemical determination of estrogen and progesterone
receptor content in human breast cancer. Computer-assisted image
analysis (QIC score) vs subjective grading (IRS). Patho Res Pract.
189:862–866. 1993.
|
|
17
|
Ganem NJ, Godinho SA and Pellman D: A
mechanism linking extra centrosomes to chromosomal instability.
Nature. 460:278–282. 2009.
|
|
18
|
Niu Y, Liu T, Tse GM, et al: Increased
expression of centrosomal alpha, gamma-tubulin in atypical ductal
hyperplasia and carcinoma of the breast. Cancer Sci. 100:580–587.
2009.
|
|
19
|
Bahmanyar S, Kaplan DD, Deluca JG, et al:
Beta-catenin is a Nek2 substrate involved in centrosome separation.
Genes Dev. 22:91–105. 2008.
|
|
20
|
Hayward DG, Newbatt Y, Pickard L, et al:
Identification by high throughput screening of viridian analogs as
biochemical and cell based inhibitors of the cell cycle regulated
NEK2 kinase. J Biomol Screen. 15:918–927. 2010.
|
|
21
|
Fry AM: The NEK2 protein kinase: a novel
regulator of centrosome structure. Oncogene. 21:6184–6194.
2002.
|
|
22
|
Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ
and Muschel RJ: Inhibition of centrosome separation after DNA
damage: a role for NEK2. Radiat Res. 162:128–135. 2004.
|
|
23
|
Hayward DG, Clarke RB, Faragher AJ, Pillai
MR, Hagan IM and Fry AM: The centrosomal kinase NEK2 displays
elevated levels of protein expression in human breast cancer.
Cancer Res. 64:7370–7376. 2004.
|
|
24
|
Shuling W, Weidong L, Shuhua L, Yahong W,
Ziyu L, Jing Z, Tieju L and Yun N: Abnormal expression of Nek2 and
β-catenin in breast carcinoma: clinicopathological correlations.
Histopathology. 59:631–642. 2011.
|
|
25
|
Gozuacik D, Chami M, Lagorce D, et al:
Identification and functional characterization of a new member of
the human Mcm protein family. Nucleic Acids Res. 2:570–579.
2003.
|
|
26
|
Labib K, Tercero JA and Diffley JF:
Uninterrupted Mcm2–7 function required for DNA replication fork
progression. Science. 288:1643–1647. 2000.
|
|
27
|
Crevel C, Ivetic A, Ohno K, et al: Nearest
neighbor analysis of Mcm protein complexes in drosophila
melanogaster. Nucl Acids Res. 29:4834–4842. 2001.
|
|
28
|
Lee JK and Hurwitz J: Possessive DNA
helices activity of the mini chromosome maintenance protein 4, 6
and 7 complexes requires forked DNA structures. Proc Natl Acad Sci
USA. 98:54–59. 2001.
|
|
29
|
Fujioka S, Shomori K, Nishihara K, Yagama
K, Nosaka K, Araki K, Araki K, et al: Expression of minichromosome
maintenance 7 (Mcm7) in small lung adenocarcinomas (pT1):
prognostic implication. Lung Cancer. 65:223–229. 2009.
|
|
30
|
Marnerides A, Vassilakopoulos TP,
Boltetsou E, et al: Immunohistochemical expression and prognostic
significance of CCND3, Mcm2 and Mcm7 in Hodgkin lymphoma.
Anticancer Res. 31:3585–3594. 2011.
|
|
31
|
Lobato S, Tafuri A, Fernandes PA, Caliari
MV, et al: Mini chromosome maintenance 7 protein is a reliable
biological marker for human cervical progressive decease. J Gyneco
Oncol. 23:11–15. 2012.
|
